Synergistic induction of CX3CL1 by TNF alpha and IFN gamma in osteoblasts from rheumatoid arthritis: involvement of NF-kappa B and STAT-1 signaling pathways by Isozaki, Takeo et al.
© 2008 Isozaki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Inﬂ  ammation Research 2008:1 19–28 19
ORIGINAL RESEARCH
Synergistic induction of CX3CL1 by TNF alpha 
and IFN gamma in osteoblasts from rheumatoid 
arthritis: involvement of NF-kappa B and STAT-1 
signaling pathways
Takeo Isozaki
Tsuyoshi Kasama
Ryo Takahashi
Tsuyoshi Odai
Kuninobu Wakabayashi
Hirohito Kanemitsu
Kyoko Nohtomi
Hiroko T Takeuchi
Satoshi Matsukura
Masakazu Tezuka
Division of Rheumatology, 
Department of Internal Medicine, 
Showa University School of Medicine, 
Tokyo, Japan, and the Department 
of Orthopedics, Denencyofu Central 
Hospital, Tokyo, Japan
Correspondence: Tsuyoshi Kasama
Division of Rheumatology, Department 
of Internal Medicine, Showa University 
School of Medicine, 1-5-8 Hatanodai, 
Shinagawa-ku, Tokyo 142-8666, Japan
Fax +81 33784 8742
Email tkasama@med.showa-u.ac.jp
Abstract: To explore the regulation of CX3CL1 in inﬂ  ammatory bone diseases, CX3CL1 
expression by osteoblasts (OB) was examined. Human OB isolated from rheumatoid arthritis 
(RA) patients, osteoarthritis patients, and normal individuals were incubated in the presence of 
cytokines. Soluble CX3CL1 levels were determined with an enzyme-linked immunosorbent 
assay. Expression of CX3CL1 mRNA was examined using quantitative real-time polymerase 
chain reaction. Although tumor necrosis factor (TNF)-α or interferon (IFN)-γ alone RA OB 
induced negligible CX3CL1 secretion, the combination of TNF-α and IFN-γ induced dramatic 
increases in both soluble CX3CL1 protein and mRNA transcripts. This synergistic effect was 
more pronounced in OB from RA than in OB from either osteoarthritis or normal individuals. 
The expression of CX3CL1 was markedly reduced by speciﬁ  c inhibitors of the nuclear factor-κB 
(NF-κB) or STAT-1 transcription factor. These ﬁ  ndings suggest that osteoblasts are an important 
cellular source of CX3CL1 and may play roles in inﬂ  ammatory bone/joint diseases.
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Introduction
The pathology of rheumatoid arthritis (RA) is characterized by the inﬁ  ltration of 
several inﬂ  ammatory cell types into the pannus and the joint ﬂ  uid, followed by tissue 
destruction. Chemokines and other inﬂ  ammatory mediators appear to play key roles in 
the pathogenesis of RA, and the coordinated production of chemokines and proinﬂ  am-
matory cytokines is likely important in the orchestration of the inﬂ  ammatory response 
(Kunkel et al 1996; Choy and Panayi 2001). Several cellular components of the joint 
contribute to the cytokine/chemokine network. Although autoreactive T cells, B cells, 
and synovial cells (including synovial ﬁ  broblasts and macrophages) have crucial roles 
in pannus formation and arthritis formation, bone-derived cells such as osteoblasts 
(OBs), osteocytes, and osteoclasts also are recognized as important cellular mediators 
of bone erosion and destruction in RA (Udagawa et al 2002). Several chemokines are 
highly expressed in bone erosive lesions (Lisignoli et al 2002). Cells involved in bone 
formation (eg, OBs) express a variety of chemokines, and OBs appear to be major 
regulators of bone remolding in both normal and pathological conditions.
During inﬂ  ammatory processes, OBs exhibit prominent induction of cytokines 
and chemokines including TNF-α, IL-6, IL-8, GRO-alpha, MCP-1, CXCL9, 
CXCL10, CXCL11, CCL2, ICAM-1, VCAM-1, and angiopoietin-1 (Zhu et al 1994; 
Takeshita et al 1995; Kurokouchi et al 1998; Lisignoli et al 1999; Kasama et al 2007). 
Several proinﬂ  ammatory cytokines such as TNF-α, IFN-γ, IL-6, and transforming 
growth factor-β have been shown to up-regulate the expression of these molecules in Journal of Inﬂ  ammation Research 2008:1 20
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osteoblasts. Nevertheless, the exact proﬁ  le of OB-derived 
chemokine expression remains unclear.
A member of the chemokine family, CX3CL1 (also 
known as fractalkine) is synthesized mainly by endo-
thelial cells (ECs) (Bazan et al 1997). The soluble form 
of   CX3CL1 (sCX3CL1) reportedly exerts a chemotac-
tic effect on monocytes, NK cells, and T lymphocytes. 
sCX3CL1 acts via its receptor, CX3CR1, as an adhesion 
molecule to promote the ﬁ  rm adhesion of a subset of 
leukocytes to ECs under conditions of physiological ﬂ  ow 
(Imai et al 1997; Umehara et al 2001). Thus, CX3CL1 
appears to possess immunoregulatory properties that affect 
inﬂ  ammatory/immune cell-EC interactions and inﬂ  amma-
tory responses. Indeed, numerous studies have implicated 
CX3CL1 in a variety of inﬂ  ammatory disorders including 
glomerulonephritis, systemic sclerosis, and systemic lupus 
erythematosus (Chen et al 1998; Blaschke et al 2003; 
Hasegawa et al 2005; Yajima et al 2005). In particular, 
CX3CL1 may play important roles in RA and rheumatoid 
vasculitis (Ruth et al 2001; Volin et al 2001; Nanki et al 
2002; Matsunawa et al 2006). Although expression of 
CX3CL1 by OBs was demonstrated recently (Shulby et al 
2004), regulatory mechanisms of CX3CL1 in OBs have not 
yet been elucidated. To further understand the expression 
and regulation of CX3CL1 in inﬂ  ammatory bone diseases 
as well as in physiological conditions, the expression of 
CX3CL1 by osteoblasts was examined in detail.
Materials and methods
Reagents
Complete medium consisted of  DMEM (Nissui Pharmaceutical 
Co., Tokyo, Japan) supplemented with 2 mM L-glutamine, 
100 U/mL penicillin, 100 μg/mL streptomycin, and 10% 
heat-inactivated FBS (Gibco Laboratories, Grand Island, NY). 
TNF-α and IFN-γ were purchased from Genzyme/Techne 
(Cambridge, MA). The NF-κB p65 small interfering (si)RNA 
(Silencer NF-κBp65 siRNA), signal transducer and activa-
tor of transcription 1 (STAT-1) siRNA (Silencer STAT-1 
siRNA), and nonsilencing siRNA (Silencer Negative Con-
trol siRNA) were obtained from Ambion (Austin, TX). The 
NF-κB inhibitor pyrrolidine dithiocarbamate was purchased 
from Sigma-Aldrich (St. Louis MO). GM-6001, a broad-
spectrum hydroxamic acid inhibitor of metalloproteases, 
was purchased from Calbiochem (Darmstadt, Germany). The 
following inhibitors were all obtained from Sigma Aldrich: 
PD98059, a mitogen-activated ERK-activated kinase (MEK) 
1/2 inhibitor; U73122, a phospholipase C (PLC) inhibitor; 
wortmannin, a phosphatidylinositol 3’-kinase (PI 3’-kinase) 
inhibitor; and N,N-dimethylsphingosine, a sphingosine 
kinase inhibitor.
Preparation of human osteoblasts
Human OBs were puriﬁ  ed from metaphyseal trabecular 
bones in the proximal femora of RA patients (n = 3), 
osteoarthritis (OA) patients (n = 2), and post-traumatic 
patients (control OBs, n = 2) during total hip arthroplasty, 
as described previously (Kasama et al 2007). Brieﬂ  y, after 
removing pieces of cortical bone, articular cartilage, and 
soft connective tissue, the fragments were cut into small 
pieces and incubated with DMEM containing 1% collage-
nase at 37 °C for 30 min, followed by extensive washing. 
The resultant bone explants were cultured in tissue culture 
plates in DMEM containing 10% FBS. When cell monolay-
ers were conﬂ  uent (after 3–5 weeks of culture), the explants 
were removed, and the cells were replated at a cell density 
of 1 × 105/mL. Cells were incubated for 3 days, then various 
stimulants were added. Conditioned culture media were col-
lected at selected times thereafter. In some experiments, cell 
lysates were obtained by the addition of an equal volume of 
0.1% Tween 20 in PBS, followed by incubation for 30 min 
on ice. The obtained cells exhibited a ﬂ  attened polygonal 
shape with multiple spindlelegs and possessed characteristics 
of the osteoblast-like phenotype such as osteocalcin expres-
sion, bone alkaline phosphatase expression, and mineraliza-
tion as determined by von Kossa staining (data not shown). 
Also human osteosarcoma cell line MG63 (from American 
Type Culture Collection, Manassas, VA) was plated at a 
cell density of 4.5 × 105/cm2 in DMEM complete medium, 
and incubated for 24 h with the indicated doses of TNF-α 
(0.2–20 ng/mL) and/or IFN-γ (1–1000 U/mL).
This study was carried out in accordance with protocols 
approved by the Human Subjects Research Committee at 
our institution, and informed consent was obtained from 
all patients.
Enzyme-linked immunosorbent assay
Soluble CX3CL1 was quantiﬁ  ed using a double ligand 
enzyme-linked immunosorbent assay (ELISA) that was 
a modiﬁ  cation of an assay described previously (Yajima 
et al 2005; Matsunawa et al 2006). Monoclonal murine 
anti-human CX3CL1 (Genzyme/Techne, 4 μg/mL) was 
used as the primary antibody (Ab), and the second-
ary Ab was biotinylated polyclonal goat anti-CX3CL1 
(Genzyme/Techne, 0.25 μg/mL). This assay detects the 
chemokine domain of human CX3CL1, and the sensitivity 
limit is ∼150 pg/mL.Journal of Inﬂ  ammation Research 2008:1 21
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Immunohistochemistry
Cell-associated CX3CL1 was visualized immunohistochemically 
by modiﬁ  cation of a previously published assay (Kasama 
et al 2001; Matsunawa et al 2006). Brieﬂ  y, OBs were grown 
to near-conﬂ  uence in an 8-well LabTech chamber slide and 
then stimulated with cytokines for 24 h. The slides were 
incubated with polyclonal goat anti-CX3CL1 Ab (R and D 
systems, Minneapolis, MN) or with pre-immune goat IgG. 
Biotinylated anti-goat IgG (Nichirei, Japan) and peroxidase-
conjugated streptavidin served as second and third reagents, 
respectively. The optimal color was developed by using 
a 3,3-diaminobenzidine tetrahydrochloride detection kit 
(Nichirei, Japan). After rinsing with distilled water, the slides 
were counterstained with Mayer's hematoxylin.
Flow cytometry
Flow cytometric analyses of CX3CL1 expression on OBs 
were carried out as described previously (Yajima et al 2005). 
OBs were labeled with monoclonal mouse PE-conjugated 
anti-CX3CL1 Ab (R and D Systems). The ﬂ  uorescence inten-
sity was measured by a three-color FACScan ﬂ  ow cytometer 
(Becton Dickinson, Mountain View, CA).
Isolation of total RNA and real-time 
polymerase chain reaction (PCR)
Total RNA was extracted from human OBs using TRIzol 
reagent (Invitrogen, Carlsbad, CA). One-microgram samples 
of total RNA were reverse transcribed into cDNA by incuba-
tion with TaqMan RT reagents (Applied Biosystems, Foster 
City, CA), ﬁ  rst for 120 min at 37  °C and then for 10 min at 
25 °C. Real-time PCR was conducted with an ABI Prism® 
7900 sequence detection system (Applied Biosystems). 
The reaction mixture included 40 ng cDNA, which was 
ampliﬁ  ed by AmpliTaq Gold DNA polymerase (Applied 
Biosystems) as described previously (Kasama et al 2007). 
For detection of CX3CL1, NF-κB, STAT-1, and ribosomal 
RNA (rRNA) expression, appropriate Assays-on-Demand™ 
primers and probes (Applied Biosystems) were used in the 
PCR. For quantiﬁ  cation, the number of target mRNA copies 
per rRNA copy was calculated, and values were expressed 
as -fold increases over control (culture medium alone). In 
some experiments, the DNA fragments ampliﬁ  ed by PCR 
were subjected to 2% agarose gel electrophoresis as described 
previously (Lu et al 2000).
siRNA transfection
Cells were seeded in 6-well plates at a density of 1.5 × 105 
cells per well. Cells were then incubated in complete medium 
without antibiotics for 24 h prior to experimentation, at 
which time they were 60% to 70% conﬂ  uent. Fifty nano-
molar siRNA against NF-κB or STAT-1 or nonsilencing 
siRNA and 10 μg/mL Lipofectamine 2000 (Invitrogen) 
in 500 μL Opti-MEM (Invitrogen) were mixed gently at 
room temperature for 20 min to allow complexes to form. 
Thereafter, 1500 μL complete medium without antibiotics 
was added, and the resultant solution was mixed and over-
laid on the cells. Cells were incubated with the siRNA/
Lipofectamine 2000 complexes for 24 h at 37 °C prior to 
the isolation of total RNA.
Statistical analysis
Data are expressed as means ± SEM and were compared by 
analysis of variance. The means of groups whose variances 
were determined to signiﬁ  cantly differ were compared using 
Student’s t-test for comparison of the means of multiple 
groups. Values of p  0.05 were considered signiﬁ  cant.
Results
Secretion and expression of OB-derived 
CX3CL1 and regulation by TNF-α 
and IFN-γ
We hypothesized that cellular interactions and inﬁ  ltration are 
important for the remodeling of bone tissues during patho-
logical as well as physiological conditions and that OBs are 
an important cellular source of chemotactic factors. To test 
this hypothesis, we ﬁ  rst determined whether OBs isolated 
from RA patients (RA OBs) could be induced to secrete the 
chemotactic factor CX3CL1. The effects of the inﬂ  ammatory 
cytokine TNF-α and the immunoregulatory cytokine IFN-γ 
on CX3CL1 secretion were examined.
Neither TNF-α (20 ng/mL) nor IFN-γ (1000 units/mL) 
signiﬁ  cantly affected CX3CL1 secretion from RA OBs as 
compared with medium alone (Figure 1a). On the other hand, 
when applied together, graded doses of either TNF-α or IFN-γ 
with IFN-γ or TNF-α, respectively, induced signiﬁ  cant dose-
dependent secretion of CX3CL1 from RA OBs (medium, 
375.4 pg/mL; TNF-α + IFN-γ, 5681.7 pg/mL; Figure 1a). 
A similar pattern of CX3CL1 secretion was observed in the 
human osteosarcoma cell line MG63 (Figure 1b).
CX3CL1 from RA OBs stimulated with both cyto-
kines was detectable in culture supernatants at 8 h, and 
levels were increased sharply at 24 h. Levels of cell-
associated CX3CL1 were greater than levels of CX3CL1 
in the supernatants until after 8 h (Figure 1c). Because 
membrane-bound CX3CL1 is cleaved to the soluble form Journal of Inﬂ  ammation Research 2008:1 22
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by metalloproteases such as ADAM17 and ADAM10 
(Garton et al 2001, Hundhausen et al 2003), the involve-
ment of proteases in the generation of sCX3CL1 was 
examined in this in vitro culture system. GM-6001, a 
broad-spectrum inhibitor of metalloproteases, was added 
to OB cultures, and CX3CL1 in culture supernatants and 
cell lysates was assessed by ELISA. As shown in Figure 
1d, GM-6001 signiﬁ  cantly inhibited CX3CL1 levels in 
supernatants of OBs stimulated with both cytokines in 
combination. While, a modest increase in cell-associated 
CX3CL1 was observed by treatment with GM-6001 on 
cytokine-stimulated OBs compared with no compounds, 
but this was not statistically signiﬁ  cant. Therefore, GM-
6001-sensitive metalloproteases may be, in part, involved 
in CX3CL1 cleavage in cytokine-stimulated OBs.
The cell-surface expression of CX3CL1 was also examined 
immunohistochemically (Figure 2a). Although small amounts 
of CX3CL1 antigen were detected in unstimulated RA 
OBs and in OBs stimulated with each cytokine alone (data 
not shown), substantially increased amounts of CX3CL1 
were observed in OBs stimulated with the combination 
of cytokines (Figure 2a). Furthermore, membrane-bound 
CX3CL1 protein in RA OBs was examined using ﬂ  ow 
cytometric analysis. As observed by ELISA and immu-
nohistochemistry, combined stimulation with TNF-α and 
IFN-γ induced enhanced expression of membrane-bound 
CX3CL1 on RA OBs (Figure 2b). To determine whether 
increased CX3CL1 antigen levels are accompanied by 
similarly increased CX3CL1 mRNA transcript levels, we 
examined the expression of OB-derived CX3CL1 mRNA 
with real-time PCR. As shown in Figure 2c, the expression 
of CX3CL1 mRNA in OBs was signiﬁ  cantly enhanced by 
both TNF-α and IFN-γ compared with culture medium or 
with either cytokine alone. This augmented expression of 
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Figure 1 Secretion of CX3CL1 from OBs and the effects of TNF-α and IFN-γ. Cultured OBs from RA patients (A) or MG63 cells (B) were incubated for 24 h with the 
indicated doses of TNF-α and/or IFN-γ. (C) RA OBs stimulated with cytokines were collected after 2, 4, 8, and 24 h of stimulation. (D) RA OBs stimulated with cytokines 
were treated with either GM-6001 or negative control compound for 24 h. CX3CL1 levels in culture supernatants and cell lysates were assayed using speciﬁ  c ELISAs. Data 
are expressed as the means ± SEM of 5 independent experiments. *p  0.01 vs control medium; **p  0.05 vs control medium.Journal of Inﬂ  ammation Research 2008:1 23
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CX3CL1 mRNA was conﬁ  rmed by agarose-gel analysis of 
PCR products (Figure 2d).
Next, the levels of CX3CL1 secretion were compared 
among OBs from patients with an inﬂ  ammatory disease 
(RA), patients with a non-inﬂ  ammatory disease (OA), and 
normal individuals. In response to the combination of TNF-α 
and IFN-γ, a signiﬁ  cantly increased amount of CX3CL1 was 
secreted into the supernatant by RA and OA OBs compared 
with normal OBs (Figure 3a). Although there appeared to 
be an obvious difference in CX3CL1 secretion between 
RA OBs and OA OBs (4629.3 pg/ml vs 3263.5 pg/mL), 
the result did not reach statistical signiﬁ  cance. However, 
enhanced CX3CL1 mRNA expression was observed in RA 
OBs stimulated with the combination of cytokines compared 
with both normal and OA OBs (p  0.05) (Figure 3b). In 
addition, receptor expression for either TNF-α or IFN-γ was 
examined on OBs from either RA patients or OA patients, 
controls, because these results demonstrated that CX3CL1 
expression from RA, OA or controls was differentially regu-
lated by TNF-α/IFN-γ. However, there were no signiﬁ  cant 
differences in their expression between RA, OA patients and 
controls by ﬂ  ow cytometry and RT-PCR.
NF-κB expression and its role 
in the cytokine-mediated induction 
of CX3CL1in OBs
To further examine the mechanisms of CX3CL1 induction in 
OBs, the expression of NF-κB mRNA in OBs was examined. 
Although the expression of NF-κB mRNA was induced by 
stimulation with either TNF-α or IFN-γ, together the two 
cytokines elicited an 8.4-fold increase in NF-κB levels within 
4 h (Figure 4a). The potential role of NF-κB in the induction 
of CX3CL1 expression was investigated by evaluating the 
capacity of anti-NF-κB siRNA to inhibit CX3CL1 expression 
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in OBs. Whereas addition of control siRNA had no speciﬁ  c 
effect on the induction of CX3CL1 expression by costimula-
tion with TNF-α and IFN-γ, the addition of siRNA targeted to 
NF-κB signiﬁ  cantly reduced the synergistic effect of TNF-α 
and IFN-γ on CX3CL1 expression at both the protein (38.5% 
suppression compared with control siRNA; Figure 4b) and 
mRNA (61.7% suppression; Figure 4c) levels.
In addition, the effect of pyrrolidine, an NF-κB inhibi-
tor, on CX3CL1 expression by OBs was examined. Consis-
tent with the siRNA inhibition, both the secretion (Figure 
5a) and mRNA expression (Figure 5b) of CX3CL1 by 
cytokine-stimulated RA OBs were signiﬁ  cantly inhibited 
by pyrrolidine. To investigate other second messengers 
involved in the induction of CX3CL1 expression by cyto-
kines, different kinase and transcription factor inhibitors 
were added to OB cultures. In contrast to pyrrolidine, 
inhibitors of MEK1/2 (PD98059; 50 μmol/L), PLC (U73122; 
1 μmol/L), PI 3’-kinase (wortmannin; 30 nmol/L), and sphin-
gosine kinase (N,N-dimethylsphingosine; 5 μmol/L) did not 
affect CXCL1 expression (data not shown).
STAT-1 expression in OBs 
and its involvement in CX3CL1 expression
The present results indicate the importance of IFN-γ and 
TNF-α in CX3CL1 expression by OBs. To further explore the 
regulatory mechanisms underlying CX3CL1 expression, we 
examined the role of STAT-1 in this induction. Although the 
expression of STAT-1 in RA OBs was not induced by TNF-α 
alone, mRNA expression of STAT-1 was up-regulated by the 
combination of IFN-γ with TNF-α and, to a lesser extent, by 
IFN-γ alone (Figure 6a). Next, siRNA against STAT-1 was 
transfected into RA OBs, and the mRNA expression and 
secretion of CX3CL-1 were examined. The up-regulated 
mRNA expression and secretion of CX3CL1 in OBs stimu-
lated by the combination of cytokines were signiﬁ  cantly 
inhibited by siRNA targeted to STAT-1, reducing the levels 
of secreted protein 69.8% (Figure 6b) and of mRNA expres-
sion 47.7% (Figure. 6c) compared with control siRNA.
Discussion
The present study clearly demonstrates that OBs from 
patients with an inﬂ  ammatory condition (RA) and even a 
non-inﬂ  ammatory condition (OA) are a prominent cellular 
source of CX3CL1 in response to the combination of  TNF-α 
and IFN-γ. Although it was demonstrated previously that 
CX3CL1 is expressed by OBs in vitro (Shulby et al 2004), 
the present report examined the regulatory mechanisms of 
CX3CL1 expression by OBs. Immunohistochemistry and 
ﬂ  ow cytometry experiments revealed increased amounts 
of intracellular CX3CL1 and membrane expression upon 
stimulation with TNF-α and IFN-γ. Furthermore, CX3CL1 
transcripts detected by real-time RT-PCR were promptly up-
regulated by cytokine stimulation. CX3CL1 protein levels in 
cell lysates reached maximal levels 8 h after co-stimulation 
with TNF-α and IFN-γ and decreased thereafter, whereas 
CX3CL1 levels in supernatants increased gradually between 
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2 and 24 h after cytokine stimulation. Also metalloproteases 
such as ADAM10 and ADAM17 (Garton et al 2001; Hundhausen 
et al 2003) appear to be important for cleaving membrane-
bound CX3CL1 into the soluble form. Consistent with 
these previous reports, GM-6001-sensitive metalloproteases 
may be, in part, involved in CX3CL1 cleavage in cytokine-
stimulated OBs.
We have shown that OBs from patients with RA have an 
enhanced capacity to express CX3CL1 compared with OBs 
from patients with a non-inﬂ  ammatory condition (OA) or 
OBs from normal individuals. Previous studies have shown 
that RA OBs produce greater amounts of chemokines such 
as CXCL1 and CCL2 under unstimulated conditions or 
inﬂ  ammatory stimuli (including IFN-γ) than do OA OBs 
(Lisignoli et al 1999, 2002). It has been well documented 
that TNF-α and IFN-γ cooperate in a variety of biological 
responses and synergistically enhance the expression of genes 
involved in immune and inﬂ  ammatory responses (Paludan 
2000). Synergistic cytokine induction can be envisaged in 
chronic inﬂ  ammatory reactions such as RA, during which 
inﬂ  ammatory or immunoregulatory cytokines, including 
TNF-α and IFN-γ, are very likely to be present (van Roon 
et al 1995; Klimiuk et al 1997).
Blaschke et al have shown that CX3CL1 markedly 
induces the secretion of matrix metalloprotease-2 (MMP-2) 
from synovial ﬁ  broblasts (Blaschke et al 2003), in addition 
to its other known functions as a chemoattractant of T cells, 
NK cells, and macrophages; an adhesion molecule; and 
an inducer of angiogenesis (Bazan et al 1997; Volin et al 
2001; Ruth et al 2001; Ancuta et al 2003). Induction of the 
MMP family plays a crucial role in the bone/joint destruc-
tion observed in RA (Tak and Bresnihan 2000). In addition, 
osteoblasts not only play a central role in bone formation 
by synthesizing multiple bone matrix proteins, but regulate 
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osteoclast maturation by soluble factors and cognate inter-
action, resulting in bone resorption. To further clarify the 
function of OG-derived CX3CL1, we tried to explore the 
biological signiﬁ  cance of CX3CL1 in osteoclast formation. 
First, recombinamt CX3CL1 was added to human peripheral 
blood monocytes derived osteoclasts, which were stimulated 
to maturate by GM-CSF and RANKL (Shinoda et al 2003). 
Second, human peripheral blood monocytes were added onto 
osteogenic cells stimulated by cytokine (TNF-α plus IFN-γ), 
and then stimulated by GM-CSF and RANKL. However, 
we could not determine any signiﬁ  cant effects (inhibition 
or stimulation) of recombinant CX3CL1 or cell-bound 
CX3CL1 on osteoclast formation or maturation (unpublished 
observation). CX3CL1, especially the soluble form, may 
have important functions at inﬂ  ammatory sites, and these 
functions may depend upon the type of stimuli or upon other 
factors including the type of activated cells, damaged organ, 
or bone/joint inﬂ  ammation.
Notably, several investigations have demonstrated that 
co-stimulation by TNF-α and IFN-γ stimulates CX3CL1 
expression by various cell types (Yoshida et al 2001; Ludwig 
et al 2002). However, until now the signaling mechanisms 
by which inﬂ  ammatory stimuli induce CX3CL1 expression 
by OBs had not been elucidated. Our ﬁ  ndings revealed 
that co-stimulation by TNF-α and IFN-γ induces CX3CL1 
expression by OBs mainly through the activation of NF-κB 
and STAT-1 pathways. It is well known that TNF-α and 
NF-κB are important for the induction and expression of 
cytokines, chemokines, and growth factors (Li and Verma 
2002; Bonizzi and Karin 2004; Jimi and Ghosh 2005) and 
play crucial roles in the pathogenesis of RA (Aggarwal 
2000). Indeed, several cell types express CX3CL1 through 
the NF-κB pathway upon stimulation by TNF-α (Garcia et al 
2000; Chandrasekar et al 2003; Chen et al 2003; Ahn et al 
2004). Because CX3CL1 induction seems to be independent 
of the MEK, PLC, sphingosine kinase, and PI 3’-kinase 
pathways, TNF-α signaling through NF-κB may be crucial 
for the expression of CX3CL1 by OBs. Furthermore, the 
activity of the NF-κB pathway may vary depending on cell 
type and on the factors induced by TNF-α.
The present study also investigated the role of the tran-
scription factor STAT-1 in CX3CL1 expression by OBs. 
STAT-1 expression by OBs was up-regulated by IFN-γ 
stimulation and by the combination of TNF-α and IFN-γ, but 
not by TNF-α alone. siRNA inhibition of STAT-1 demon-
strated that STAT-1 appears to be important for up-regulating 
CX3CL1 in OBs. STAT-1 plays crucial roles in several 
inﬂ  ammatory conditions including RA (Wang et al 1995; 
Kasperkovitz et al 2004), as well as in bone remodeling 
(Kim et al 2003; Takayanagi et al 2005). The present results 
suggest that STAT-1 regulation of CX3CL1 expression by 
OBs may be important in these situations.
In conclusion, OBs appear to be an important cellular 
source of CX3CL1. A more complete understanding of the 
functions of OB-derived CX3CL1 in pathological condi-
tions such as RA should provide insights into inﬂ  ammatory 
disease pathogenesis and suggest new strategies for clinical 
intervention.
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